vs
Side-by-side financial comparison of Protalix BioTherapeutics, Inc. (PLX) and SWK Holdings Corp (SWKH). Click either name above to swap in a different company.
Protalix BioTherapeutics, Inc. is the larger business by last-quarter revenue ($9.1M vs $8.7M, roughly 1.0× SWK Holdings Corp). On growth, SWK Holdings Corp posted the faster year-over-year revenue change (-29.7% vs -49.9%). SWK Holdings Corp produced more free cash flow last quarter ($26.8M vs $1.6M). Over the past eight quarters, Protalix BioTherapeutics, Inc.'s revenue compounded faster (-6.7% CAGR vs -12.5%).
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
SWK Holdings Corp is a specialty finance firm focused on the healthcare and life sciences sectors. It provides tailored financing solutions including royalty monetization, structured debt, and asset-backed lending to biotech, pharmaceutical, medical device and diagnostic companies, with its core market centered in North America.
PLX vs SWKH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.1M | $8.7M |
| Net Profit | $-5.5M | $-19.4M |
| Gross Margin | 49.4% | — |
| Operating Margin | -51.1% | 9.9% |
| Net Margin | -60.3% | — |
| Revenue YoY | -49.9% | -29.7% |
| Net Profit YoY | -184.8% | -430.2% |
| EPS (diluted) | $-0.06 | $-1.59 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.1M | $8.7M | ||
| Q3 25 | $17.9M | $10.9M | ||
| Q2 25 | $15.7M | $10.1M | ||
| Q1 25 | $10.1M | $11.8M | ||
| Q4 24 | $18.2M | $12.4M | ||
| Q3 24 | $18.0M | $10.4M | ||
| Q2 24 | $13.5M | $10.8M | ||
| Q1 24 | — | $11.4M |
| Q4 25 | $-5.5M | $-19.4M | ||
| Q3 25 | $2.4M | $8.8M | ||
| Q2 25 | $164.0K | $3.5M | ||
| Q1 25 | $-3.6M | $4.5M | ||
| Q4 24 | $6.5M | $5.9M | ||
| Q3 24 | $3.2M | $3.5M | ||
| Q2 24 | $-2.2M | $3.7M | ||
| Q1 24 | — | $468.0K |
| Q4 25 | 49.4% | — | ||
| Q3 25 | 53.4% | — | ||
| Q2 25 | 62.5% | — | ||
| Q1 25 | 19.1% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 53.4% | — | ||
| Q2 24 | 29.8% | — | ||
| Q1 24 | — | — |
| Q4 25 | -51.1% | 9.9% | ||
| Q3 25 | 11.9% | 61.3% | ||
| Q2 25 | 7.5% | 46.1% | ||
| Q1 25 | -41.0% | 68.6% | ||
| Q4 24 | 39.6% | 44.7% | ||
| Q3 24 | 22.2% | 39.2% | ||
| Q2 24 | -18.0% | 8.3% | ||
| Q1 24 | — | 9.5% |
| Q4 25 | -60.3% | — | ||
| Q3 25 | 13.2% | 80.7% | ||
| Q2 25 | 1.0% | 35.2% | ||
| Q1 25 | -35.8% | 38.4% | ||
| Q4 24 | 35.6% | 47.5% | ||
| Q3 24 | 18.0% | 33.3% | ||
| Q2 24 | -16.4% | 33.9% | ||
| Q1 24 | — | 4.1% |
| Q4 25 | $-0.06 | $-1.59 | ||
| Q3 25 | $0.03 | $0.72 | ||
| Q2 25 | $0.00 | $0.29 | ||
| Q1 25 | $-0.05 | $0.37 | ||
| Q4 24 | $0.10 | $0.47 | ||
| Q3 24 | $0.03 | $0.28 | ||
| Q2 24 | $-0.03 | $0.30 | ||
| Q1 24 | — | $0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $14.7M | $42.8M |
| Total DebtLower is stronger | — | $33.0M |
| Stockholders' EquityBook value | $48.2M | $235.1M |
| Total Assets | $82.3M | $272.4M |
| Debt / EquityLower = less leverage | — | 0.14× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.7M | $42.8M | ||
| Q3 25 | $13.6M | $10.2M | ||
| Q2 25 | $17.9M | $8.0M | ||
| Q1 25 | $19.5M | $29.8M | ||
| Q4 24 | $19.8M | $5.9M | ||
| Q3 24 | $27.4M | $17.2M | ||
| Q2 24 | $23.4M | $5.5M | ||
| Q1 24 | — | $5.5M |
| Q4 25 | — | $33.0M | ||
| Q3 25 | — | $33.0M | ||
| Q2 25 | — | $33.0M | ||
| Q1 25 | — | $33.0M | ||
| Q4 24 | — | $33.0M | ||
| Q3 24 | — | $33.0M | ||
| Q2 24 | — | $33.0M | ||
| Q1 24 | — | $33.0M |
| Q4 25 | $48.2M | $235.1M | ||
| Q3 25 | $52.9M | $254.2M | ||
| Q2 25 | $49.9M | $246.5M | ||
| Q1 25 | $45.2M | $292.7M | ||
| Q4 24 | $43.2M | $288.7M | ||
| Q3 24 | $32.4M | $283.4M | ||
| Q2 24 | $28.6M | $282.8M | ||
| Q1 24 | — | $279.9M |
| Q4 25 | $82.3M | $272.4M | ||
| Q3 25 | $82.3M | $289.4M | ||
| Q2 25 | $78.5M | $285.7M | ||
| Q1 25 | $73.9M | $331.3M | ||
| Q4 24 | $73.4M | $332.2M | ||
| Q3 24 | $61.6M | $321.3M | ||
| Q2 24 | $91.5M | $321.0M | ||
| Q1 24 | — | $322.0M |
| Q4 25 | — | 0.14× | ||
| Q3 25 | — | 0.13× | ||
| Q2 25 | — | 0.13× | ||
| Q1 25 | — | 0.11× | ||
| Q4 24 | — | 0.11× | ||
| Q3 24 | — | 0.12× | ||
| Q2 24 | — | 0.12× | ||
| Q1 24 | — | 0.12× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.0M | $27.3M |
| Free Cash FlowOCF − Capex | $1.6M | $26.8M |
| FCF MarginFCF / Revenue | 17.8% | 308.1% |
| Capex IntensityCapex / Revenue | 4.4% | 5.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-13.6M | $43.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0M | $27.3M | ||
| Q3 25 | $-3.7M | $906.0K | ||
| Q2 25 | $-5.2M | $7.8M | ||
| Q1 25 | $-5.1M | $8.3M | ||
| Q4 24 | $4.0M | $23.0M | ||
| Q3 24 | $4.1M | $6.3M | ||
| Q2 24 | $-3.6M | $5.4M | ||
| Q1 24 | — | $4.4M |
| Q4 25 | $1.6M | $26.8M | ||
| Q3 25 | $-4.2M | $557.0K | ||
| Q2 25 | $-5.7M | $7.7M | ||
| Q1 25 | $-5.4M | $8.2M | ||
| Q4 24 | $3.6M | $22.9M | ||
| Q3 24 | $4.0M | $6.3M | ||
| Q2 24 | $-3.8M | $5.4M | ||
| Q1 24 | — | — |
| Q4 25 | 17.8% | 308.1% | ||
| Q3 25 | -23.7% | 5.1% | ||
| Q2 25 | -36.2% | 77.0% | ||
| Q1 25 | -53.0% | 69.1% | ||
| Q4 24 | 19.6% | 185.3% | ||
| Q3 24 | 22.4% | 60.4% | ||
| Q2 24 | -28.1% | 49.7% | ||
| Q1 24 | — | — |
| Q4 25 | 4.4% | 5.9% | ||
| Q3 25 | 2.8% | 3.2% | ||
| Q2 25 | 2.8% | 0.6% | ||
| Q1 25 | 3.0% | 0.8% | ||
| Q4 24 | 2.3% | 1.1% | ||
| Q3 24 | 0.5% | 0.3% | ||
| Q2 24 | 1.3% | 0.2% | ||
| Q1 24 | — | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | -1.58× | 0.10× | ||
| Q2 25 | -31.91× | 2.21× | ||
| Q1 25 | — | 1.82× | ||
| Q4 24 | 0.61× | 3.93× | ||
| Q3 24 | 1.27× | 1.82× | ||
| Q2 24 | — | 1.47× | ||
| Q1 24 | — | 9.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
SWKH
| Finance Receivables Segment | $8.4M | 96% |
| Other | $329.0K | 4% |
